Genencor Launches Improved Acid Fungal Protease for Use in the Ethanol Industry
Genencor International, a division of Danisco A/S, announced the availability of a new acid fungal protease enzyme product for use in the ethanol industry. The new product, called FERMGEN(TM) will be introduced at the Fuel Ethanol Workshop in Milwaukee, Wisconsin.
According to the company, the new FERMGEN(TM) protease enzyme offers a number of benefits which include: faster ethanol fermentation rates and yield for corn, milo or wheat based substrates as compared with fermentations without acid fungal protease; increased essential yeast nutrients in the form of amino acids, peptides and free amino nitrogen; hydrolyzes protein matrices in the corn kernel that bind the various fractions thereby enabling the hydrolysis of the "hard" to hydrolyze starch; and effectiveness at a pH of 3.0 - 4.5, which is complimented by the average current fermentation pH that is employed in the fuel ethanol industry.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Biogen Idec and Alnylam Alliance to Develop Therapeutics for Treatment of Progressive Multifocal Leukoencephalopathy (PML)
William S. Marth Appointed to AMRI's Board of Directors
Florida_Dental_Association
IXICO and PsiOxus Therapeutics win significant funding from government-backed Biomedical Catalyst
Novartis gains exclusive rights to Debio 025, an antiviral agent as potential first-in-class hepatitis C therapy - Novartis to make upfront payment to Debiopharm Group, with Debiopharm eligible for milestones and royalties on future sales
Merck & Co. Announces New Name for its Animal Health Division
PolyTherics appoints new Chairman
Germany Begins its First AIDS Vaccine Trial, Partnering with IAVI
MedImmune to Collaborate With National Institutes of Health to Develop Pandemic Influenza Vaccine
Pharmexa presents data from influenza program
Dental_public_health
